On or around 09/20/2017 (Ongoing date of last review)
Filing Date: November 11, 2014
According to the law firm press release, this case alleges that the defendants made materially false or misleading statements with respect to the safety and efficacy of the Company’s drug Macrilen™. A November 6, 2014, press release by the Company brought these facts to light by announcing that the FDA had issued a Complete Response Letter refusing to approve the Company’s New Drug Application because of “the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.
An amended complaint was filed on April 10, 2015.
On September 16, 2015, the Court granted Defendant's Motion to Dismiss with leave to amend. Plaintiffs filed an amended complaint on October 14.
Company & Securities Information
Defendant: Aeterna Zentaris Inc.
Industry: Biotechnology & Drugs
Ticker Symbol: AEZS
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.